期刊文献+

HPLC法测定大鼠血浆中呱氨托美丁及其代谢产物MED-5与托美丁的浓度 被引量:2

Determination of amtolmetin guacil and its active metabolite MED-5 and tolmetin in rat plasma by high-performance liquid chromatography
原文传递
导出
摘要 目的建立同时测定大鼠血浆中呱氨托美丁(MED-15)及其代谢产物MED-5与托美丁浓度的HPLC法。方法血浆样品用乙腈沉淀蛋白,采用HypersilODS C_(18)柱(250mm×4.6mm,5μm)进行分离,以甲醇-2%冰醋酸(60:40,V/V)为流动相,流速1.0mL·min^(-1);紫外检测波长313 nm。结果大鼠血浆中MED-15、MED-5和托美丁线性范围分别是0.050~5.6、0.042~5.4和0.039~5 mg·L^(-1)(r分别为0.995 1、0.995 7、0.999 0);定量下限分别为0.050、0.042和0.039mg·L^(-1);平均相对回收率分别是100.3%、99.4%和99.9%,平均绝对回收率分别88.9%、87.8%和88.7%;日内、日间精密度均<12%。血浆样品的稳定性符合要求。结论本研究所建立的大鼠血浆中MED-15、MED-5和托美丁浓度测定的HPLC方法灵敏、准确、精密、稳定,适用于大鼠体内MED-15的药动学研究。 AIM To develop a method for the determination of amtolmetin guacil(MED-15) and its active metabolite MED-5 and tolmetin in rat plasma by HPLC method.METHODS Plasma samples were extracted with acetonitrile. The separation was carried out by using a Hypersil ODS C_(18) column(250 mm×4.6 mm,5μm) with a mobile phase of methanol-2%glacial acetic acid(60:40,V/V) at a flow rate of 1.0 mL·min^(-1),and detection wave length was set at 313 ran.RESULTS The linear ranges for MED-15,MED-5 and tolmetin were 0.050 - 5.6 mg·L^-1, 0.042-5.4mg·L^-1 and 0.039-5.0 mg·L^-1(r= 0.995 1,r=0.995 7,r = 0.999 0),respectively.The limit of quantitation of MED-15,MED-5 and tolmetin was 0.05,0.042 and 0.039 mg·L^1,respectively.The relative recoveries of MED-15,MED-5 and tolmetin were 100.3%,99.4%and 99.9%,respectively.The absolute recoveries were 88.9%,87.8%and 88.7%,respectively.The intra-day RSD and inter-day RSD were both less than 12%.CONCLUSION The developed method for the quantification of MED-15,MED-5 and tolmetin in rat plasma is sensitive,accurate, precise and stable,and is suitable for the study on the pharmacokinetics of MED-15 in rats.
出处 《中国临床药学杂志》 CAS 2011年第4期213-216,共4页 Chinese Journal of Clinical Pharmacy
关键词 呱氨托美丁 MED-5 托美丁 高效液相色谱法 amtolmetin guacil MED-5 tolmetin HPLC
  • 相关文献

参考文献5

  • 1Blmsari VK, Mahadik MV, Dhaneshwar SR. Application of a stabilityindicating HPTLC method for quantitative analysis of amtolmetin guacil in a pharmaceutical dosage form[J]. Acta Chromatographica,2009,21 (2) : 299.
  • 2Kirkova M, Alexandova A, Kesiova M, et al. In vivo effects of amtolmetin guacil on lipid peroxidation and antioxidant defence systems. Comparison with non-selective and COX-2 selective NSAIDs[J]. Auton Autacoid Phannaeol, 2007, 27(2) :99.
  • 3Kirkova M,Kesiova M,Konstantinova S, et al. In vivo effects of amtolmetin guacil on lipid peroxidation and antioxidant defence systems in different models of gastrointestinal injury[J]. Auton Autacoid Pharmacol, 2007,27(1) :63.
  • 4李飞娥,周华.HPLC法测定人血浆中呱氨托美丁活性代谢物托美丁和MED5的浓度[J].中国药师,2010,13(1):26-28. 被引量:1
  • 5Mohamed S, Gtinther S, Wolfgang MS, et al. Sample pretreatment and determination of non steroidal anti-inflammatory drugs (NSAIDs) in pharmaceutical formulations and biological samples (blood, plasma, erythrocytes) by I-IPLC-UV-MS and μ-HPLC[J]. Curt Med Chem, 2005, 12(5) : 573.

二级参考文献4

  • 1Ezio T, Luisella B, Carla MM, et al. The mechanism of action of amtolmetin guacyl, a new gastroprotective nonsteroidal anti-inflammatory drug [ J ]. European Journal of Pharmacology, 2000,387 : 233 -244.
  • 2Ezio T,Luisella B ,Carla MM ,et al. Impact on the bowel of amtolmetin guacyl,a new gastroprotectlve non-steroidal anti-inflammatory drug[J]. European Journal of Pharmacology,2003,467 : 173 -183.
  • 3Maneinelli A, Bruno G, et al. High-performance liquid chromatographic evaluation of Med 15 and its metabolites Med 5 and tolmetin in rat plasma[J]. J Chromatogr, 1991,553 (1-2) :81-86.
  • 4Annunziato L, di Renzo G, Cardace E. A bioequivalence study of tablet and powder formulations of the nonsteroidal anti-inflammatory drug 2-methoxyphenyl 1-methyl-5-(p-methylbenzoylpyrrol)-2-acetamidoacetate [ J]. Clin Ter, 1993, 142(1 Pt 2) :11-17.

同被引文献9

  • 1Imen Trabelsi,Wacim Bejar,Dorra Ayadi,Hichem Chouayekh,Radhouane Kammoun,Samir Bejar,Riadh Ben Salah.Encapsulation in alginate and alginate coated-chitosan improved the survival of newly probiotic in oxgall and gastric juice[J].International Journal of Biological Macromolecules.2013
  • 2Kirkova M, Alexandova A, Kesiova M, et al. In vivo e~~ects o}" amtolmetin guacyl on lipid peroxidation and antioxidant de- ~ence systems. Comparison with non-selective and COX-2 se- lective NSAIDs[J]. Auton Autaeoid Pharmacol,2007,27 (2): 99-104.
  • 3Hotha KK, Dasari VB, Shaik AN, et al. Species difference in the in vitro and in vivo metabolism of amtolmetin guacil[J]. Arzneimit t elforschung, 2010,60 (11 ) : 667-74.
  • 4Evaluation of intestinal absorption of amtolmetinguacyl in rats:Breast cancer resistant protein as a primary barrier o{ oral bioavailability[J].Life Sci,2013,92(3) :245 251.
  • 5Ni Z,Bikadi Z,Rosenberg M F,et al. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2) [J]. Curr Drug Metab, 2010,11 (7) : 603-17.
  • 6Sarkadi B, Orban TI, Szakacs G, et al. Evaluation of ABCG2 expression in human embryonic stem ceils: crossing the same river twice? [J]. Stem Cells,2010,28(1):174-6.
  • 7Rob ey RW, To KK, Polgar O, et a l. ABCG2: a perspective [J].Adv Drug Deliv Rev,2009,61 (1):3-13.
  • 8刘东,刘宇,向道春,张程亮.呱氨托美丁及其代谢产物在大鼠体内药动学[J].中国医院药学杂志,2011,31(11):898-901. 被引量:2
  • 9徐艳娇,冯承阳,张程亮,向道春,李喜平,刘东.呱氨托美汀及其代谢产物在大鼠体内的组织分布[J].中国医院药学杂志,2014,34(24):2120-2124. 被引量:1

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部